Latest news with #organic growth
Yahoo
5 hours ago
- Business
- Yahoo
Argus cuts Arthur J. Gallagher target, sees buying opportunity on selloff
Argus lowered the firm's price target on Arthur J. Gallagher (AJG) to $330 from $370 and keeps a Buy rating on the shares following the Q2 report. The views the recent pullback in the shares as a buying opportunity. Argus expects organic growth of more than 9% in the company's brokerage unit in 2025, compared to its forecast of 6%-8%. The company has 40 term sheets signed or being prepared, representing approximately $500M of annualized revenue, the analyst tells investors in a research note. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on AJG: Disclaimer & DisclosureReport an Issue Arthur J. Gallagher acquires MACK Insurance Services; terms not disclosed Arthur J. Gallagher acquires Novi for undisclosed amount Arthur J. Gallagher price target lowered to $322 from $345 at UBS Arthur J. Gallagher Reports Strong Earnings and Growth Arthur J. Gallagher price target lowered to $352 from $372 at Piper Sandler Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Wall Street Journal
31-07-2025
- Business
- Wall Street Journal
Schneider Electric's Double-Digit Growth Driven by Data Center Deals
Schneider Electric SU -2.76%decrease; red down pointing triangle posted double-digit organic growth in its energy management business for the first half, supported by a strong pipeline of deals in the data-center segment. The French group on Thursday said it remains well placed to seize opportunities in its end markets, despite an environment of heightened uncertainty.
Yahoo
24-07-2025
- Business
- Yahoo
Nestle struggles amid weak China market
Nestle said Tuesday its net profit fell in the first half of the year as the Swiss food giant behind Nespresso coffee capsules and KitKat chocolate bars struggles to turn around its fortunes amid sluggish consumer spending in China. The company whose brands also include Purina dog food, Maggi bouillon cubes, Gerber baby food and Nesquik chocolate-flavoured drinks, reported a 10.3 percent drop in first half profits to 5.1 billion Swiss francs ($6.4 billion). Sales, however, only dipped by 1.8 percent to 44.2 billion francs, which was due in large part to passing on higher cocoa and coffee prices to consumers, although faced even greater headwinds from the strong Swiss currency. "We are also taking decisive measures to strengthen our business in Greater China," said chief executive Laurent Freixe. The company said China, which has suffered sluggish domestic consumption amid a deflationary price environment, had a 0.7 percentage point impact on organic growth in the second quarter. Overall, the company reported 2.9 percent quarterly organic growth, which strips out currency effects and other elements to measure performance. Nestle warned China would continue to weigh on growth as it invested to turn around its performance. Nestle's shares fell 3.5 percent in a Swiss market that was flat overall, as the sales figures missed the analyst consensus calculated by Swiss financial news agency AWP. Net profit came in slightly higher than expected. Nestle made a surprise switch of its chief executive least year amid soft spending by consumers for food and household goods. Nestle's share price slumped by nearly a quarter last year, raising concerns in Switzerland, where pension funds invest heavily in the company. The company launched a number of measures to boost its product offering and cut costs. That was reflected in better organic growth in the second quarter compared to the same period last year, and Nestle said that it was expected to continue for the rest of the year. Nestle said it was maintaining its 2025 guidance "despite factoring in increased headwinds". It aims for an underlying trading operating profit margin of at least 16 percent this year, compared to 17.2 percent in 2024. It came in at 16.5 percent in the first half of the year. noo/rl/yad Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23-07-2025
- Business
- Yahoo
Why Thermo Fischer Stock Is Rising Wednesday
Thermo Fisher Scientific Inc. (NYSE:TMO) on Wednesday reported second-quarter 2025 adjusted earnings of $5.36 per share, beating the street view of $5.23. Quarterly sales of $10.86 billion increased 3% year-over-year, beating the analyst consensus estimate of $10.68 billion. Organic revenue growth was 2%. 'The agility of our organization, powered by the PPI Business System, allowed us to effectively adapt to current market conditions, actively manage our cost base and deliver strong operational results in the second quarter,' said Marc Casper, chairman, president and CEO of Thermo Fisher Scientific. The company said, 'PPI is helping us adjust our supply chains in the tariff environment and to actively manage our cost base.' Also Read: Management Change: Thermo Fisher Scientific announced Stephen Williamson, senior vice president and CFO, has decided to retire from the company, effective March 31, 2026. The company's board of directors appointed Jim Meyer, vice president of financial operations, to succeed Williamson as CFO, effective March 1, 2026. Guidance: During an earnings conference call, Thermo Fisher Scientific forecasts 2025 revenue of $43.6 billion-$44.2 billion, compared to prior guidance of $43.3 billion-$44.2 billion and the consensus of $43.71 billion. View more earnings on TMO The company expects adjusted earnings of $22.22-$22.84 per share, compared to prior guidance of $21.76-$22.84 and consensus of $22.33. The company adds that the U.S.-China tariff situation has improved significantly compared to prior assumptions. Last week, Thermo Fisher Scientific announced an expansion of its strategic partnership with Sanofi SA (NASDAQ:SNY) to enable additional U.S. drug product manufacturing. The terms of the deal were not disclosed. Under the agreement, Thermo Fisher will acquire Sanofi's steriles manufacturing site in Ridgefield, New Jersey, and continue to manufacture a portfolio of therapies for Sanofi. In addition, Thermo Fisher will expand use of the site to meet the growing demand from pharma and biotech customers for U.S. manufacturing capacity. The Ridgefield site is a sterile fill-finish and packaging facility with over 200 employees who will join Thermo Fisher following the completion of the transaction. The transaction is expected to be completed in the second half of 2025. Upon completion of the transaction, Sanofi's Ridgefield facility will become part of Thermo Fisher's pharma services business within its Laboratory Products and Biopharma Services segment. Price Action: TMO stock is up 13.2% at $483.94 at the last check on Wednesday. Read Next:Photo: Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? THERMO FISHER SCIENTIFIC (TMO): Free Stock Analysis Report This article Why Thermo Fischer Stock Is Rising Wednesday originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
